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Stavudine (d4T) was, until recently, one of the most widely prescribed antiretroviral drugs
worldwide. While there has been a major shift away from d4T use in resource-limited countries, a
large number of patients have previously received (or continue to receive) d4T, and many have
developed peripheral neuropathy. The identification of genetic predictors of increased risk might
suggest novel therapeutic targets for such patients. In AIDS Clinical Trials Group protocol 384,
antiretroviral-naïve patients were randomized to d4T/didanosine (ddI)- or zidovudine/lamivudine-
containing regimens. Data from d4T/ddI recipients were analyzed for genome-wide associations
(approximately 1 million genetic loci) with new onset distal sensory peripheral neuropathy.
Analyses involved 254 patients (49 % White, 34 % Black, 17 % Hispanic), comprising 90
peripheral neuropathy cases (32 grade 1, 35 grade 2, 23 grade 3) and 164 controls. After correcting
for multiple comparisons, no polymorphism was consistently associated with neuropathy among
all patients, among White, Black, and Hispanic patients analyzed separately, both in genome-wide
analyses (threshold, P<5.0×10−8) and focused on 46 neuropathy-associated genes (threshold,
P<3.5×10−5). In the latter analyses, the lowest P values were in KIF1A among Whites
(rs10199388, P=8.4×10−4), in LITAF among Blacks (rs13333308, P=6.0×10−6), and in NEFL
among Hispanics (rs17763685, P=5.6×10−6). Susceptibility to d4T/ddI-associated neuropathy is
not explained by a single genetic variant with a marked effect.
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Introduction
Antiretroviral therapy has greatly reduced human immunodeficiency virus (HIV)-1-
associated morbidity and mortality. The dideoxynucleoside reverse transcriptase inhibitors
didanosine (ddI) and stavudine (d4T) have been widely prescribed in multidrug
antiretroviral regimens, but severe toxicities associated with these “D-drugs” have markedly
curtailed their prescribing (Dalakas 2001). Such toxicities including peripheral neuropathy,
hepatic steatosis, lactic acidosis, and peripheral lipoatrophy are likely the consequence of
inhibition of mitochondrial DNA polymerase gamma (Lewis et al. 2001).
Until recently, d4T was one of the most widely prescribed antiretroviral drugs worldwide.
Over the past several years, there has been a major shift from d4T use to tenofovir use in
resource-limited countries, a change that had already occurred in most developed countries.
Large numbers of patients, however, have previously received (or continue to receive) d4T
for many months or years, and many have developed peripheral neuropathy. The
identification of genetic predictor(s) of increased risk for peripheral neuropathy might
suggest therapeutic targets for such patients.
Previous reports involving patients of European and African ancestry have suggested
associations between heritable variations in mitochondrial DNA (so-called mitochondrial
haplogroups) and increased risk for peripheral neuropathy with ddI/d4T-containing regimens
(Canter et al. 2010; Hulgan et al. 2005). The present study examined genetic associations
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between nuclear variants and risk of developing peripheral neuropathy among HIV-infected
patients who initiated d4T/ddI-containing regimens in a prospective clinical trial.
Methods
This retrospective, case-control genome-wide association study (GWAS) utilized data and
specimens that had been prospectively collected from participants in AIDS Clinical Trials
Group (ACTG) protocol 384, who consented for genetic analysis under protocol A5128.
Study ACTG 384 was a multicenter randomized trial designed to compare antiretroviral
drug regimens (ddI/d4T or zidovudine/lamivudine given with efavirenz, nelfinavir or both)
as initial treatment for HIV-1 infection (Robbins et al. 2003). Patients in the present analyses
enrolled in ACTG 384 in 1998 and 1999 in the USA and received ddI/d4T-containing
regimens. Cases were patients who developed clinical signs or symptoms of distal sensory
neuropathy within the first 96 weeks of initiating ddI/ d4T. Controls were patients who did
not develop such signs or symptoms within 96 weeks of initiating ddI/d4T. Patients with
peripheral neuropathy documented prior to initiating ddI/d4T were excluded from these
analyses. Peripheral neuropathy was assessed at each study visit and was categorized as
grade 1 (asymptomatic with sensory alteration on exam or minimal paresthesia causing no or
minimal interference with usual social and functional activities), grade 2 (sensory alteration
or paresthesia causing greater than minimal interference with usual social and functional
activities), and grade 3 (sensory alteration or paresthesia causing inability to perform usual
social and functional activities).
Genotyping of DNA extracted from whole blood was by Illumina Human-1M Duo Beadchip
(Illumina Inc., San Diego, CA, USA) and was available from a separate HIV
immunogenomics project (Pereyra et al. 2010). Population ancestry was assessed by
projecting genetic assay data onto HapMap Phase III data (Pereyra et al. 2010). Analyses
were limited to nuclear polymorphisms. Hereafter, we refer to non-Hispanic White, non-
Hispanic Black, and Hispanic patients as White, Black, and Hispanic, respectively.
Quality control was applied to genetic assay data as follows. Variants with missingness >2
% or minor allele frequencies <5 % were excluded. Data from samples with exceptionally
high or low heterozygosity values (|F|>0.1) or genotyping failure >2 % were excluded. A
total of 936,149 polymorphisms passed quality control. Within each race/ethnicity group,
associations were assessed for genome-wide significance (P<5.0×10−8) by logistic
regression. To examine associations across all three race/ethnicity groups together, meta-
analyses were also performed. Further analyses focused on polymorphisms in the set of
neuropathy-associated genes listed in the Inherited Peripheral Neuropathies Mutation
Database (Timmermen 2011) and also in DNMT1 and KIF1A (list of genes provided in
Supplemental On-line Table 1). For analyses involving neuropathy-associated gene,
polymorphisms within 100 kb upstream and downstream of each gene were included, and
the genome-wide significance threshold was P<3.5×10−5. Analyses were performed
separately for grade ≥1, grade ≥2, and grade 3 peripheral neuropathies. Quality control of
genotype data and genetic association analyses were performed using PLINK v1.07 (Purcell
et al. 2007). Additional statistical analyses were done with the R statistical package version
2.13.1.
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A total of 254 patients were included in these analyses, comprising 90 peripheral neuropathy
cases (32 grade 1, 35 grade 2, and 23 grade 3) and 164 controls. There were 125 (49.0 %)
White, 86 (34 %) Black, and 43 (17 %) Hispanic patients as assessed by principal
components. In meta-analyses, involving all 254 White, Black, and Hispanic patients, that
focused on the 90 grade ≥1 peripheral neuropathy cases, no polymorphism was genome-
wide significant (Fig. 1). The lowest P value was intronic in KRR1 (rs11540407, odds ratio
(OR)= 2.6; P=9.6×10−6). Separate meta-analyses limited to the 58 grade ≥2 peripheral
neuropathy cases and limited to the 23 grade 3 peripheral neuropathy cases did not similarly
show any polymorphism to be genome-wide significant. Polymorphisms with the lowest P
values were not consistent between analyses nor were they consistent between populations
(Table 1).
Using whole genome data, separate analyses were performed in White, Black, and Hispanic
patients and separately for grade ≥1, grade ≥2, and grade 3 peripheral neuropathies (i.e., nine
separate analyses) (Supplemental on-line Table 2). Polymorphisms with the lowest P values
are as follows. In White patients with grade 3 peripheral neuropathy, the polymorphism with
the lowest P value was intronic in IL2RA (rs12722486, OR=38.2; 95 % confidence interval
(CI)=6.6– 219.6; P=1.5×10−9). In Black patients with grade 3 peripheral neuropathy, the
polymorphism with the lowest P value was intronic in ZNF648 (rs7554128, OR=48.5; 95 %
CI= 5.7–414; P=5.7×10−8). In Hispanic patients with grade ≥2 peripheral neuropathy, the
polymorphism with the lowest P value was within 100 kb of RSP04 (rs502716, OR=28; 95
% CI=6.8–114.7; P=3.2×10−8)
Further analyses were limited to 46 neuropathy-associated genes and comprised 1,395
polymorphisms. In a meta-analysis, involving White, Black, and Hispanic patients, that
focused on all 90 grade ≥1 peripheral neuropathy cases, no polymorphism was genome-wide
significant at P<3.5×10−5. The polymorphism with the lowest P value was intronic in FGD4
(rs1909509, OR=2.1; P=9.6×10−4). Separate meta-analyses limited to grade ≥2 as well as
grade 3 peripheral neuropathy cases did not show any polymorphism to be genome-wide
significant.
Considering only the 46 neuropathy-associated genes, separate analyses were conducted in
White, Black, or Hispanic patients and for grade ≥1, grade ≥2, and grade 3 peripheral
neuropathies (Supplemental on-line Table 3). Polymorphisms with the lowest P values were
as follows. In White patients with grade 3 peripheral neuropathy, the lowest P value was
within 100 kb of KIF1A (rs10199388, OR=5.3; 95 % CI= 1.8–15.3; P=8.4×10−4). In Black
patients with grade ≥2 peripheral neuropathy, the polymorphism with the lowest P value
was within 100 kb of LITAF (rs13333308, OR=17.1; 95 % CI=2.1–138.9; P=4.6×10−4).
This polymorphism also had the lowest P value in an analysis limited to 23 grade 3
peripheral neuropathy cases (rs13333308, OR=32.3; 95 % CI=3.7–284.9; P=6.0×10−6). In
Hispanic patients with grade ≥2 peripheral neuropathy, the polymorphism with the lowest P
value was within 100 kb of NEFL (rs6557786, OR=23.2; 95 % CI=4.3–125.6; P=4.7×10−6).
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Among patients exposed to ddI/d4T-containing regimens in ACTG 384, who were evaluable
for genetic associations with new onset sensory peripheral neuropathy within the first 96
weeks of treatment, no polymorphism was consistently genome-wide significant. This was
so in analyses of polymorphisms across the entire nuclear genome, and in analyses focused
on polymorphisms in neuropathy-associated genes. This was also so in analyses that
included all grade ≥1 peripheral neuropathy cases and in analyses limited to grade ≥2 and
grade 3 peripheral neuropathy cases. Furthermore, polymorphisms with the lowest P values
were not consistent across analyses limited to grade ≥1, grade ≥2, and grade 3 peripheral
neuropathies. The fact that associations did not reproduce across populations nor across
grades of neuropathy suggests that such associations may not also reproduce in other
cohorts.
In White patients with grade 3 peripheral neuropathy, the polymorphism with the lowest P
value was in IL2RA. The interleukin-2 receptor alpha (IL2RA) gene encodes a regulator of
immune responses (Maier et al. 2009) but has no clear relevance to neuronal physiology. In
Black patients with grade 3 peripheral neuropathy, the polymorphism with the lowest P
value was in ZNF648, which may be involved in transcriptional regulation. In Hispanic
patients with grade ≥2 peripheral neuropathy, the polymorphism with the lowest P value
was near RSPO4 (which encodes R-spondin 4, possibly involved in Wnt/beta-catenin
signaling pathways) (Blaydon et al. 2006) and ANGPT4 (which encodes angiopoietin 4,
involved in vascular development and angiogenesis) (Olsen et al. 2006), genes with no
specific relevance to neuronal physiology.
In analyses limited to neuropathy-associated genes, a meta-analysis considering all grades of
peripheral neuropathy showed the lowest P value for a polymorphism in FGD4. This gene
encodes frabin which is involved in peripheral nerve myelination, and FGD4 mutations have
been associated with autosomal recessive Charcot-Marie-Tooth Type 4H (Charcot-Marie-
Tooth disease comprises of a clinically and genetically diverse group of inherited disorders
of peripheral nerves) (Delague et al. 2007). Meta-analysis of grade 3 peripheral neuropathy
showed the lowest P value for a polymorphism near KIF1B. In White patients, the
polymorphism with the lowest P value for association with all grades of peripheral
neuropathy and with grade 3 peripheral neuropathy was in KIF1A, while in Black patients,
the lowest P values were for polymorphisms in LITAF. KIF1A encodes a protein involved in
anterograde transport of organelles along axonal microtubules, and KIF1A mutations have
been associated with spastic paraplegia and hereditary sensory neuropathy (Klebe et al.
2012; Riviere et al. 2011), while KIF1B encodes for a protein involved in apoptosis and
axonal transport of membranous organelles. Mutations to KIF family genes have been
associated with Charcot-Marie-Tooth disease type 2A, while LITAF mutations have been
associated with Charcot-Marie-Tooth disease type 1C (CMT1C) (Street et al. 2003). In
Hispanic patients, the polymorphism with the lowest P value for association with all grades
of peripheral neuropathy was in NEFL, which encodes the neurofilament light polypeptide.
Mutations in NEFL have been associated with Charcot-Marie-Tooth disease types 2E and 1F
(Jordanova et al. 2003; Shin et al. 2008)
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There were limitations to this study. The sample size was modest, so only polymorphisms
with marked effects could have achieved genome-wide significance. In addition, peripheral
neuropathy in ACTG 384 was based on signs and symptoms, rather than formal neurologic
evaluation assessments.
In summary, among patients exposed to ddI/d4T-containing regimens in the ACTG 384, no
genetic polymorphism was consistently associated with new onset distal sensory peripheral
neuropathy at genome-wide significance. Polymorphisms identified herein (e.g., in KIF1A,
LITAF, and NEFL) warrant replication in other cohorts of HIV-infected patients who have
developed D-drug-associated peripheral neuropathy.
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Refer to Web version on PubMed Central for supplementary material.
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Manhattan plot of associations between genetic polymorphisms and grade ≥1 sensory
peripheral neuropathy by meta-analysis. The −log10 of P values are shown. The genome-
wide significance threshold is P=5.0×10−8
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Table 1
Polymorphisms with the lowest P values for association with sensory peripheral neuropathy
Case/control Entire genomea Neuropathy-associated genesa,b
Gene Polymorphism Odds ratio P value Gene Polymorphism Odds ratio P value
Grade ≥1 90/164 KRR1 rs11540407 2.6 9.6 × 10–6 FGD4 rs1909509 2.1 9.6 × 10–4
Intergenic rs9518599 2.5 1.1 × 10–5 FGD4 rs7298165 1.9 1.8 × 10–3
KRR1 rs1552039 2.6 1.1 × 10–5 FGD4 rs6488066 1.9 2.2 × 10–3
ACE2 rs1514280 3.6 1.2 × 10–5 RAD52 rs1051669 1.8 3.4 × 10–3
KRR1 rs2070162 2.6 1.3 × 10–5 NDRG1 rs2930004 1.7 4.3 × 10–3
Grade ≥2 58/164 SASH1 rs8641 3.1 5.8 × 10–6 FAM134B c rs149511 0.4 4.7 × 10
–3
SASH1 c rs208740 2.9 9.0 × 10
–6 FGD4 rs1909509 2.1 5.4 × 10–3
ST8SIA2 c rs12913269 3.4 1.3 × 10
–5 W1SP1 rs2929965 0.5 5.6 × 10–3
ST8SIA2 c rs2129797 3.4 1.4 × 10
–5
LITAF c rs12595973 0.5 7.7 × 10
–3
NTF3 rs6332 2.7 1.7 × 10–5 KIF1A c rs4234121 0.4 9.2 × 10
–3
Grade 3 23/164 ST8SIA2c rs12913269 6.5 3.2 × 10
–7
KIF1B c rs11587309 2.7 5.1 × 10
–3
ST8SIA2c rs2129797 6.4 3.5 × 10
–7 KIF1A rs10198394 2.4 7.3 × 10–3
Intergenic rs4397851 5.3 1.5 × 10–6 NDRG1 rs10505606 2.4 7.7 × 10–3
ADAMTS2 rs6873892 6.1 2.1 × 10–6 NDRG1 rs2233326 2.4 1.1 × 10–2
ST8SIA2c rs12910290 5.1 2.8 × 10
–6 KIF1B rs10492970 7.1 1.1 × 10–2
a
Meta-analyses were performed to combine results from White, Black, and Hispanic groups
b
The neuropathy-associated genes from the Inherited Peripheral Neuropathies Mutation Database plus DNMT1 and KIF1A are listed in
Supplemental On-line Table 1
c
These polymorphisms are within 100 kb of the named gene
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